[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"expert:pl:interim-cfo-poznan-11":3},{"id":4,"slug":5,"experience_min":6,"experience_max":7,"availability":8,"public_description":9,"tags":10,"date_created":14,"rating":15,"education":16,"languages":17,"competences":21,"missions":28,"role":37,"region":44,"industries":49,"translations":61},11,"interim-cfo-poznan-11",14,19,"available","Finansowanie projektów R&D w biotechnologii i medtech. Znajomość regulacji FDA\u002FEMA i modeli finansowania innowacji.",[11,12,13],"R&D Finance","Pharma","Regulacje","2026-04-29T13:18:11.143Z",4.6,"PWr, MBA, ACCA",[18,19,20],"Polski","Angielski","Hiszpański",[22,23,24,25,26,27],"R&D financing","Grant management","FDA\u002FEMA compliance","M&A pharma","Transfer pricing","SR&ED tax credits",[29,33],{"period":30,"company":31,"result":32},"2022–2024","Biotech scale-up (anonimowo)","Pozyskanie 35M EUR finansowania serii B, struktura grant + equity.",{"period":34,"company":35,"result":36},"2020–2021","MedTech (anonimowo)","Przygotowanie spółki do due diligence przez globalny fundusz.",{"id":38,"name":39,"short_label":39,"color":40,"translations":41},1,"CFO","#D14D72",[42],{"name":39,"languages_code":43},"pl-PL",{"id":45,"name":46,"translations":47},4,"Poznań",[48],{"name":46,"languages_code":43},[50,55],{"industry_id":51},{"id":52,"name":12,"translations":53},20,[54],{"name":12,"languages_code":43},{"industry_id":56},{"id":57,"name":58,"translations":59},21,"MedTech",[60],{"name":58,"languages_code":43},[]]